Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition

Pritam Das, M. Paul Murphy, Linda H. Younkin, Steven G Younkin, Todd E. Golde

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Vaccinations with Aβ1-42 have been shown to reduce amyloid burden in transgenic models of Alzheimer's disease (AD). We have further tested the efficacy of Aβ1-42 immunization in the Tg2576 mouse model of AD by immunizing one group of mice with minimal Aβ deposition, one group of mice with modest Aβ deposition, and one group with significant Aβ deposition. The effects of immunization on Aβ deposition were examined using biochemical and immunohistochemical methods. In Tg2576 mice immunized prior to significant amyloid deposition, Aβ1-42 immunization was highly effective. Biochemically extracted Aβ40 and Aβ42 levels were significantly reduced and immunohistochemical plaque load was also reduced. Immunization of mice with modest amounts of pre-existing Aβ deposits selectively reduced Aβ42 without altering Aβ40, although plaque load was reduced. In contrast, in Tg2576 mice with significant pre-existing Aβ loads, Aβ1-42 immunization only minimally decreased Aβ42 levels, whereas no alteration in Aβ40 levels or in plaque load was observed. These results indicate that in Tg2576 mice, Aβ1-42 immunization is more effective at preventing additional Aβ accumulation and does not result in significant clearance of pre-existing Aβ deposits.

Original languageEnglish (US)
Pages (from-to)721-727
Number of pages7
JournalNeurobiology of Aging
Volume22
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Amyloid
Transgenic Mice
Immunization
Alzheimer Disease
Vaccination

Keywords

  • Aβ vaccination
  • Aβ40
  • Aβ42
  • Alzheimer's disease
  • Amyloid plaques
  • Tg2576 mice

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)

Cite this

Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. / Das, Pritam; Murphy, M. Paul; Younkin, Linda H.; Younkin, Steven G; Golde, Todd E.

In: Neurobiology of Aging, Vol. 22, No. 5, 2001, p. 721-727.

Research output: Contribution to journalArticle

Das, Pritam ; Murphy, M. Paul ; Younkin, Linda H. ; Younkin, Steven G ; Golde, Todd E. / Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. In: Neurobiology of Aging. 2001 ; Vol. 22, No. 5. pp. 721-727.
@article{bfd265ba1b9643a1846bddaf5b69f83f,
title = "Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition",
abstract = "Vaccinations with Aβ1-42 have been shown to reduce amyloid burden in transgenic models of Alzheimer's disease (AD). We have further tested the efficacy of Aβ1-42 immunization in the Tg2576 mouse model of AD by immunizing one group of mice with minimal Aβ deposition, one group of mice with modest Aβ deposition, and one group with significant Aβ deposition. The effects of immunization on Aβ deposition were examined using biochemical and immunohistochemical methods. In Tg2576 mice immunized prior to significant amyloid deposition, Aβ1-42 immunization was highly effective. Biochemically extracted Aβ40 and Aβ42 levels were significantly reduced and immunohistochemical plaque load was also reduced. Immunization of mice with modest amounts of pre-existing Aβ deposits selectively reduced Aβ42 without altering Aβ40, although plaque load was reduced. In contrast, in Tg2576 mice with significant pre-existing Aβ loads, Aβ1-42 immunization only minimally decreased Aβ42 levels, whereas no alteration in Aβ40 levels or in plaque load was observed. These results indicate that in Tg2576 mice, Aβ1-42 immunization is more effective at preventing additional Aβ accumulation and does not result in significant clearance of pre-existing Aβ deposits.",
keywords = "Aβ vaccination, Aβ40, Aβ42, Alzheimer's disease, Amyloid plaques, Tg2576 mice",
author = "Pritam Das and Murphy, {M. Paul} and Younkin, {Linda H.} and Younkin, {Steven G} and Golde, {Todd E.}",
year = "2001",
doi = "10.1016/S0197-4580(01)00245-7",
language = "English (US)",
volume = "22",
pages = "721--727",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition

AU - Das, Pritam

AU - Murphy, M. Paul

AU - Younkin, Linda H.

AU - Younkin, Steven G

AU - Golde, Todd E.

PY - 2001

Y1 - 2001

N2 - Vaccinations with Aβ1-42 have been shown to reduce amyloid burden in transgenic models of Alzheimer's disease (AD). We have further tested the efficacy of Aβ1-42 immunization in the Tg2576 mouse model of AD by immunizing one group of mice with minimal Aβ deposition, one group of mice with modest Aβ deposition, and one group with significant Aβ deposition. The effects of immunization on Aβ deposition were examined using biochemical and immunohistochemical methods. In Tg2576 mice immunized prior to significant amyloid deposition, Aβ1-42 immunization was highly effective. Biochemically extracted Aβ40 and Aβ42 levels were significantly reduced and immunohistochemical plaque load was also reduced. Immunization of mice with modest amounts of pre-existing Aβ deposits selectively reduced Aβ42 without altering Aβ40, although plaque load was reduced. In contrast, in Tg2576 mice with significant pre-existing Aβ loads, Aβ1-42 immunization only minimally decreased Aβ42 levels, whereas no alteration in Aβ40 levels or in plaque load was observed. These results indicate that in Tg2576 mice, Aβ1-42 immunization is more effective at preventing additional Aβ accumulation and does not result in significant clearance of pre-existing Aβ deposits.

AB - Vaccinations with Aβ1-42 have been shown to reduce amyloid burden in transgenic models of Alzheimer's disease (AD). We have further tested the efficacy of Aβ1-42 immunization in the Tg2576 mouse model of AD by immunizing one group of mice with minimal Aβ deposition, one group of mice with modest Aβ deposition, and one group with significant Aβ deposition. The effects of immunization on Aβ deposition were examined using biochemical and immunohistochemical methods. In Tg2576 mice immunized prior to significant amyloid deposition, Aβ1-42 immunization was highly effective. Biochemically extracted Aβ40 and Aβ42 levels were significantly reduced and immunohistochemical plaque load was also reduced. Immunization of mice with modest amounts of pre-existing Aβ deposits selectively reduced Aβ42 without altering Aβ40, although plaque load was reduced. In contrast, in Tg2576 mice with significant pre-existing Aβ loads, Aβ1-42 immunization only minimally decreased Aβ42 levels, whereas no alteration in Aβ40 levels or in plaque load was observed. These results indicate that in Tg2576 mice, Aβ1-42 immunization is more effective at preventing additional Aβ accumulation and does not result in significant clearance of pre-existing Aβ deposits.

KW - Aβ vaccination

KW - Aβ40

KW - Aβ42

KW - Alzheimer's disease

KW - Amyloid plaques

KW - Tg2576 mice

UR - http://www.scopus.com/inward/record.url?scp=0034746897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034746897&partnerID=8YFLogxK

U2 - 10.1016/S0197-4580(01)00245-7

DO - 10.1016/S0197-4580(01)00245-7

M3 - Article

VL - 22

SP - 721

EP - 727

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 5

ER -